Monoclonal Anti-MMAF specific Antibody, Rabbit IgG (1M1G10) (MALS verified)

Catalog # MMF-MY2213

Specificity

Specifically recognizes MMAF and does not recognize MMAE.

Source

Monoclonal Anti-MMAF specific Antibody, Rabbit IgG (1M1G10) is a Rabbit monoclonal antibody recombinantly expressed from HEK293 cells.

Clone

1M1G10

Isotype

Rabbit IgG | Rabbit Kappa

Conjugate

Unconjugated

Immunogen

MMAF-BSA.

Application

Application	Recommended Usage
ELISA	0.1-125 ng/mL

Purification

Protein A purified / Protein G purified

Formulation

Lyophilized from 0.22 μm filtered solution in PBS, pH7.5 with trehalose as protectant.

Contact us for customized product form or formulation.

Reconstitution

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Storage

For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:

- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.

Bioactivity-ELISA



Immobilized IgG1-MMAF at 0.1 μg/mL (100 μL/well) can bind Monoclonal Anti-MMAF specific Antibody, Rabbit IgG (1M1G10) (Cat. No. MMF-MY2213) with a linear range of 0.1-8 ng/mL (QC tested).



Serial dilutions of MMAF were added into Monoclonal Anti-MMAF specific Antibody, Rabbit IgG (1M1G10) (Cat. No. MMF-MY2213): IgG1-MMAF binding reactions. The half maximal inhibitory concentration (IC50) is 0.1106 μg/mL (Routinely tested).

Cross Verification



ELISA binding of Monoclonal Anti-MMAF specific Antibody, Rabbit IgG (1M1G10) (Cat. No. MMF-MY2213) with Doxorubicin-ADC, Disitamab Vedotin (RC48), IgG1-MMAF, Trastuzumab Deruxtecan, Sacituzumab Govitecam and Trastuzumab-DM1 conju-gated antibody respectively.

The coating antibody was Monoclonal Anti-MMAF specific Antibody, Rabbit IgG (1M1G10) (Cat. No. MMF-MY2213), used at 1 μg/mL concentration. The primary an-tibody were different payload conjugated antibodies, including Doxorubicin-ADC, Disitamab Vedotin (RC48), IgG1-MMAF, Trastuzumab Deruxtecan, Sacituzumab Govitecam and Trastuzumab-DM1 conjugated antibodies used at 0.25 μg/mL con-centration. The secondary antibody was HRP conjugated Anti-Human-IgG-Fc Anti-body (6F11C8), mAb (Acro, Cat. No. IGG-LY69) used at 1:10000 concentration.

Monoclonal Anti-MMAF specific Antibody, Rabbit IgG (1M1G10) (Cat. No. MMF-MY2213) is specific to IgG1-MMAF and has no cross-reactivity with Doxorubi-cin-ADC, Disitamab Vedotin (RC48), Trastuzumab Deruxtecan, Sacituzumab Govitecam and Trastuzumab-DM1 (Routinely tested).

Background

Monomethyl auristatin F (MMAF) is a potent mitotic inhibitor that inhibits tubulin polymerization. MMAF is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) to treat several cancer types. Anti-MMAF antibody is a rabbit monoclonal antibody specifically reacts with MMAF without MMAE, which is more sensitive than mouse antibody. The anti-MMAF antibody is a useful reagent in PK assay to determine conjugated antibodies.